Introduction {#Sec1}
============

Pancreatic cancer is associated with one of the poorest prognoses of any cancer because early detection is difficult and it progresses rapidly \[[@CR1]--[@CR3]\]. The number of deaths from pancreatic cancer is increasing in Japan. In fact, more than 30,000 deaths from pancreatic cancer in 2013 slightly exceeded the number of deaths from liver cancer in the same year \[[@CR4]\].

Pancreatic fibrosis is one of the histopathologic findings at the time of the desmoplastic reaction associated with chronic pancreatitis or pancreatic cancer. Pancreatic stellate cells (PSCs) were first isolated and identified in the pancreas in 1998 \[[@CR5], [@CR6]\]. It was found that PSCs are similar to liver stellate cells and play a pivotal role in pancreatic fibrosis. In the normal pancreas, PSCs are quiescent and store cytoplasmic vitamin A-containing lipid droplets \[[@CR7]\]. Inflammatory stimulation or signals from cancer cells activate PSCs, which develop a myofibroblast-like morphology and produce an extracellular matrix \[[@CR7]\]. Activated PSCs secrete various growth factors and cytokines, such as fibroblast growth factor, transforming growth factor-β, stromal cell-derived factor 1, and interleukin-6 \[[@CR8]\].

Podoplanin (PDPN), a 38-kDa type I transmembrane glycoprotein, is known as a marker of lymphatic endothelial cells \[[@CR9]\]. In normal tissues, PDPN is expressed in kidney podocytes \[[@CR10]\], alveolar type I cells \[[@CR11]\], osteocytes \[[@CR12]\], basal keratinocytes \[[@CR13]\], and mesothelial cells \[[@CR13]\]. Recently, PDPN was found in several other cancers, such as brain tumors \[[@CR14]\], squamous cell carcinomas \[[@CR15]\], germ cell tumors \[[@CR16]\], and mesotheliomas \[[@CR17]\]. It has been reported that PDPN expression is associated with malignancy in malignant astrocytic tumors \[[@CR14]\]. PDPN is also found in some stromal fibroblasts, and an abundance of PDPN-positive stromal fibroblasts is associated with poor prognosis in lung adenocarcinoma, invasive breast cancer, and esophageal squamous cell carcinoma patients \[[@CR18]--[@CR20]\]. Since pancreatic cancer is rich in fibrous tissues, we investigated the correlation between PDPN expression in stromal fibroblasts in invasive ductal carcinoma of the pancreas (IDCP) and prognosis in humans.

Materials and methods {#Sec2}
=====================

Patients and pancreatic cancer samples {#Sec3}
--------------------------------------

Pancreatic cancer samples were obtained from 95 patients with IDCP, who underwent surgery at the University of Yamanashi Hospital between 1995 and 2013. Table [1](#Tab1){ref-type="table"} summarizes the clinicopathological characteristics of the patients. The histological diagnosis of the specimens was confirmed based on the criteria of the uploaded World Health Organization classification \[[@CR21]\]. The stage was graded according to the Union for International Cancer Control (UICC) classification, 7th edition \[[@CR22]\]. There were 57 men and 38 women, ranging in age from 46 to 83 years (median 70.0). One patient had stage 0 disease, five had stage IA, three had stage IB, 29 had stage IIA, 56 had stage IIB, and one had stage III. This study was approved by the Ethics Committee of Yamanashi University (approved no. 1565) and was performed in accordance with the ethical standards of the Declaration of Helsinki and its later amendments. Serum carcinoembryonic antigen, carbohydrate antigen 19-9, Duke pancreatic monoclonal antigen type 2, and s-pancreas antigen-1 levels were measured at least every 3 months. Computed tomography from the chest to pelvis was performed at least every 6 months. Survival was measured from the time of pancreatic resection until death or censor. The follow-up duration ranged from 3 to 191 months.Table 1Clinicopathological characteristics of the 95 patients with invasive ductal carcinoma of the pancreasVariablesNumber of patients%PDPN positive area (%)11.83 (0.45--36.29)Age (years)70.0 (46--83)Sex Male5760 Female3840Histologic grade G12829.5 G25557.9 G31212.6Tumor size (mm)27.9 (3--90)Microscopic venous invasion Yes8387.4 No1212.6Microscopic lymphatic vessel invasion Yes7073.7 No2526.3UICC T category 011.1 166.3 233.2 38488.4 411.1UICC N category 03941.1 15658.9UICC stage 011.1 IA55.3 IB33.2 IIA2930.5 IIB5658.9 III11.1*UICC* Union for International Cancer Control, *PDPN* podoplanin

Immunohistochemistry for D2-40 and α-SMA {#Sec4}
----------------------------------------

Formalin-fixed, paraffin-embedded tissue specimens were cut into 4-µm sections. Each section was mounted on a silane-coated glass slide, deparaffinized, and treated in antigen retrieval solution for 15 min at 120 °C using Dako REAL Target Retrieval Solution (Dako, Carpentaria, CA, USA). Endogenous peroxidase was quenched by incubation at room temperature in 0.3% H~2~O~2~, followed by rinsing with phosphate-buffered saline. Endogenous biotin was quenched using the Dako Biotin Blocking System (Dako). Sections were blocked using 5% normal blocking serum for 20 min. Mouse monoclonal to D2-40 antibodies (1:40; Abcam, Cambridge, UK) were applied overnight at 4 °C to stain PDPN. Rabbit polyclonal to α-smooth muscle actin antibodies (α-SMA, 1:200; Abcam) were applied for 2 h at room temperature. Following incubation, immunoperoxidase staining was completed using a Vectastain ABC elite kit (Vector Laboratories, Burlingame, CA, USA) and 3,3′-diaminobenzidine-tetrachloride as a chromogen. The D2-40-positive area was calculated from three different (100×) fields and is expressed as a percentage of the total area of the field using PhotoShop and Image J software. To calculate the cutoff value of the PDPN-positive area, a histogram was created (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Histogram of podoplanin (PDPN) expression. A histogram was created to calculate the cutoff value of the PDPN-positive area

Statistical analysis {#Sec5}
--------------------

Data are expressed as mean ± standard error of the mean (SEM). Comparisons between two groups were assessed using the unpaired *t* test. Associations between different categorical variables were assessed using the *χ* ^2^ test. Survival rates were calculated using the Kaplan--Meier method, and significant differences in survival were determined by the log-rank test. The Cox proportional hazards model served for uni- and multivariable survival analysis. *p* \< 0.05 was considered significant.

Results {#Sec6}
=======

Analysis of PDPN expression in pancreatic cancer by immunohistochemistry for D2-40 {#Sec7}
----------------------------------------------------------------------------------

We performed immunohistochemical staining for D2-40 and α-SMA to evaluate PDPN expression in pancreatic cancer (Fig. [2](#Fig2){ref-type="fig"}). The areas that expressed PDPN in the pancreatic cancer also expressed α-SMA, a marker of stromal fibroblasts \[[@CR23]\]. The PDPN-positive area in the pancreatic cancers ranged from 0.45 to 36.29% (median 11.83). A histogram was produced to establish the cutoff value of the PDPN-positive area, which was 11.83%, being the median value of the PDPN-positive areas. Patients with high expression of PDPN accounted for 52.6% of the patients (*n* = 50). There was no significant difference in clinicopathologic factors, except for the PDPN-positive area, between the group with high PDPN expression (high PDPN group) and the group with low PDPB expression (low PDPN group; Table [2](#Tab2){ref-type="table"}).Fig. 2Hematoxylin-eosin (H&E) and immunohistochemical staining for podoplanin (PDPN) and αSMA in invasive ductal carcinoma of the pancreas. Immunohistochemical staining for PDPN (**b**, **c**) and αSMA (**d**) was performed as described in "[Materials and methods](#Sec2){ref-type="sec"}". Representative photomicrographs are shown. PDPN-expressing areas in the pancreatic cancer also expressed α-SMA. Original magnification, ×40 (**a**, **b**) and ×100 (**c**, **d**) Table 2Relationships between podoplanin expression and clinicopathologic factorsVariablesHigh PDPN expressionLow PDPN expression*p* value*n* = 50 (52.6%)*n* = 45 (47.4%)Number of patients%Number of patients%PDPN positive area (%)20.216.74\<0.0001Age (years)69.2690.926Sex0.675 Male29582862.2 Female21421737.8Histologic grade0.241 G112241635.6 G233662248.9 G3510715.6Tumor size (mm)28.327.50.791Microscopic venous invasion0.152 Yes46923782.2 No48817.8Microscopic lymphatic vessel invasion0.141 Yes40803066.7 No10201533.3UICC T category0.569 00012.2 14824.4 21224.4 344884088.9 41200UICC N category0.826 020401942.2 130602657.8UICC stage0.521 00012.2 IA4812.2 IB1224.4 IIA14281533.3 IIB30602657.8 III1200Recurrence0.409 Yes33662657.8 No17341942.2Statistical significances were calculated using the student's *t* test or the *χ* ^2^ test*PDPN* podoplanin

Correlation between PDPN expression in pancreatic cancer and prognosis {#Sec8}
----------------------------------------------------------------------

The high PDPN group had significantly poorer disease-free survival (DFS) and disease-specific survival (DSS) rates than the low PDPN group (Fig. [3](#Fig3){ref-type="fig"}). The median survival times for the high and low PDPN groups were 659 and 1212 days, respectively. We then analyzed survival according to the presence of lymph node metastasis. In the patients without lymph node metastasis, there was no significant difference in DFS or DSS according to PDPN expression, but in those with lymph node metastases, the high PDPN group had significantly poorer DFS and DSS rates than the low PDPN group (Fig. [4](#Fig4){ref-type="fig"}). There was no significant difference in the PDPN-positive area between patients with and those without lymph node metastasis (Fig. [5](#Fig5){ref-type="fig"}).Fig. 3Comparison of survival curves by the Kaplan--Meier survival method for invasive ductal carcinoma of the pancreas according to podoplanin expression. Patients with high PDPN expression had a significantly poorer prognosis than those with low PDPN expression. \**p* \< 0.05 and \*\**p* \< 0.01 vs. low PDPN expression by the log-rank test Fig. 4Comparison of survival curves by the Kaplan--Meier survival method for invasive ductal carcinoma of the pancreas according to lymph node metastasis. In patients without lymph node metastasis, there was no significant difference in the survival rate according to PDPN expression. In patients with lymph node metastases, patients with high PDPN expression had a significantly poorer prognosis than those with low PDPN expression. \**p* \< 0.05 vs. low PDPN expression without lymph node metastasis by the log-rank test Fig. 5Analysis of the ratio of the podoplanin (PDPN)-positive area between patients with vs. those without lymph node metastasis. The ratio of the PDPN-positive area between patients with and those without LN metastasis is shown. Data represent the mean ± standard error of the mean. There was no significant difference according to PDPN expression by the unpaired *t* test. *LN* lymph node

Focusing on the tumor size, in patients with tumors ≤20 mm, there was no significant difference in DFS or DSS according to PDPN expression, but in those with tumors \>20 mm, the high PDPN group had significantly poorer DFS and DSS rates than the low PDPN group (Fig. [6](#Fig6){ref-type="fig"}). There was no correlation between PDPN expression and tumor size (Fig. [7](#Fig7){ref-type="fig"}).Fig. 6Comparison of survival curves by Kaplan--Meier survival method for invasive ductal carcinoma of the pancreas according to tumor size. In patients with tumors ≤20 mm, there was no significant difference in the survival rate according to PDPN expression. In patients with tumors \>20 mm, those with high PDPN expression had a significantly poorer prognosis than those with low PDPN expression. \**p* \< 0.05 and \*\**p* \< 0.01 vs. low PDPN expression in patients with tumors \>20 mm by the log-rank test Fig. 7Immunohistochemical staining for podoplanin (PDPN) in invasive ductal carcinoma of the pancreas (IDCP). Immunohistochemical staining for PDPN was performed as described in "[Materials and methods](#Sec2){ref-type="sec"}". A scatter plot of the ratio of the PDPN-positive area in IDCP and tumor size is shown. There was no correlation

Prognostic factors {#Sec9}
------------------

We adopted factors found to be significant by univariate analysis, based on the multivariate Cox proportional hazards analysis. A high expression of PDPN was an independent risk factor for DSS (relative risk (RR) = 2.153, *p* = 0.022) and tumor size \>20 mm was an independent risk factor for both DFS (RR = 2.514, *p* = 0.013) and DSS (RR = 2.535, *p* = 0.032; Table [3](#Tab3){ref-type="table"}).Table 3Univariate and multivariate survival analysis (Cox regression model) of clinicopathologic factors and podoplanin expressionFactorsDFSDSSUnivariateMultivariateUnivariateMultivariate*p* valueHazard ratio95% CI*p* value*p* valueHazard ratio95% CI*p* valuePDPN positive area: \<11.83 vs. ≥11.83%0.047NS0.0062.1531.116--4.1530.022Age: \<65 vs. ≥65 years0.547NA0.842NASex: female vs. male0.663NA0.528NAHistologic grade: G1 vs. G2 and G30.189NA0.0032.5921.159--5.7950.020Tumor size: ≤20 vs. \>20 mm\<0.0012.5141.211--5.2200.0130.0022.5351.081--5.9430.032Microscopic venous invasion: no vs. yes0.366NA0.980NAMicroscopic lymphatic vessel invasion: no vs. yes0.126NA0.651NAUICC T category: T0, T1, and T2 vs. T3 and T40.014NS0.047NSUICC N category: N0 vs. N1\<0.001NS0.021NSUICC stage: 0-IIA vs. IIB/III\<0.0012.2231.203--4.1050.0110.011NS*DFS* disease-free survival, *DSS* disease-specific survival, *CI* confidence interval, *NA* not adopted, *NS* not significant, *UICC* Union for International Cancer Control, *PDPN* podoplanin

Discussion {#Sec10}
==========

The expression of stromal fibroblasts markers, including α-SMA, vimentin, desmin, fibroblast specific protein-1, and fibroblast-activation protein, is reported to vary depending on the local microenvironment of tumors \[[@CR23]\]. Apte et al. reported that α-SMA-positive activated PSC also expressed glial fibrillary acidic protein or/and desmin in pancreatic cancer \[[@CR24]\]. Recent studies investigating the roles of PSCs in pancreatic cancer have identified a mechanism of interaction among proliferation, invasion, and metastasis \[[@CR7], [@CR8], [@CR25]--[@CR31]\]. In the present study, PDPN-expressing stromal cells in pancreatic cancer also expressed α-SMA, suggesting that they were most likely derived from PSCs (Fig. [2](#Fig2){ref-type="fig"}).

PDPN expression in stromal fibroblasts in pancreatic cancer was reported to be associated with lymphatic invasion, vascular invasion, the tumor size, histological grade, UICC classification T stage, and a shorter survival period \[[@CR32]\]. Those results indicate that PDPN expression is associated with the progression of carcinoma in local recurrence, hematogenous metastasis, and lymphogenous metastasis \[[@CR32], [@CR33]\]. The present study found no significant difference in clinicopathologic factors between the high and low PDPN groups (Table [2](#Tab2){ref-type="table"}). There were also no significant differences between PDPN expression and the incidence of lymph node metastases or the size of tumors (Figs. [5](#Fig5){ref-type="fig"}, [7](#Fig7){ref-type="fig"}). PDPN could be related to tumor growth, leading to poor prognosis, and its expression might be determined by the genotype of each tumor. Importantly, DFS and DSS were significantly poorer in the high PDPN group (Fig. [3](#Fig3){ref-type="fig"}). Thus, as PDPN expression is involved in the prognosis of pancreatic cancer patients, it may be a useful marker to identify patients with a poor prognosis after surgery.

Based on previous reports, lymphatic invasion, vascular invasion, tumor size, pathological grade, and UICC classification T stage are all useful for pathologic staging; however, no effective molecular targeting therapy after surgery has been established. In this regard, PDPN may be a useful and effective molecular target for therapy. Indeed, Kato et al. developed a cancer-specific monoclonal antibody against human PDPN, which reacted with PDPN-expressing cancer cells, but not with normal cells \[[@CR34]\]. Although this antibody is promising for molecular targeting therapy against PDPN-expressing cancers, PDPN is expressed only on the stromal fibroblasts surrounding tumors in pancreatic cancer. Conversely, Suzuki-Inoue et al. reported that PDPN expressed in cancer cells promotes platelet aggregation and it may also be involved in migration, invasion, metastasis, and the malignant progression of cancer cells \[[@CR35]\]. Thus, PDPN expressed in stromal fibroblasts may be involved in cancer progression, leading to a poor prognosis via mechanisms of multiple growth factors derived from activated platelets. Further investigations are needed to realize useful targeting therapy against PDPN in pancreatic cancer.

Conclusions {#Sec11}
===========

Podoplanin expression in stromal fibroblasts is associated with the poor prognosis of patients with large tumors or lymph node metastases of pancreatic cancer. Our findings suggest that patients with high expression of PDPN should be followed-up more closely after surgery. PDPN may become an important target of therapy for pancreatic cancer.
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